Skip to Main Content
Table 1

Characteristics of the subjects

Number of patients 98 
Age (mean ± SD, range, y) 62.7 ± 9.8 (30-80) 
Sex (male/female) 76/22 
Smoking history Missing = 15 
    Never-smoked 17 
    Ex-smoker (quit >1 y before diagnosis) 12 
    Current smoker 54 
Histology  
    ADC 41 
    BAC 
    SQC 40 
    NSCLC 11 
    ADC +BAC vs. non-ADC 47 vs. 51 
Gefitinib treatment  
    First-line therapy 
    Second-line therapy 44 
    Third-line therapy 45 
    Fourth-line therapy 
Response to gefitinib Evaluable patients = 80 
    PR 20 (25%) 
    SD 18 (22.5%) 
    PD 42 (52.5%) 
Number of patients 98 
Age (mean ± SD, range, y) 62.7 ± 9.8 (30-80) 
Sex (male/female) 76/22 
Smoking history Missing = 15 
    Never-smoked 17 
    Ex-smoker (quit >1 y before diagnosis) 12 
    Current smoker 54 
Histology  
    ADC 41 
    BAC 
    SQC 40 
    NSCLC 11 
    ADC +BAC vs. non-ADC 47 vs. 51 
Gefitinib treatment  
    First-line therapy 
    Second-line therapy 44 
    Third-line therapy 45 
    Fourth-line therapy 
Response to gefitinib Evaluable patients = 80 
    PR 20 (25%) 
    SD 18 (22.5%) 
    PD 42 (52.5%) 

Abbreviations: ADC, adenocarcinoma; BAC, bronchiolo-alveolar cell carcinoma; SQC, squamous cell carcinoma; PR, partial remission; SD, stable disease; PD, progressive disease.

Close Modal

or Create an Account

Close Modal
Close Modal